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Aim: To present a series of patients with a clinical diagnosis of periocular keratoacanthoma and assess the
incidence of histologically proven invasive squamous cell carcinoma (SCC).
Methods: This retrospective case series included all patients with periocular tumours seen in the authors’
unit between 1996 and 2004, and who were initially diagnosed with keratoacanthoma based on the
clinical presentation.
Results: Twelve patients (eight males, four females) were clinically diagnosed with keratoacanthoma. The
final histological diagnosis revealed two cases (16.7%) of invasive SCC, and 10 cases (83.3%) of
keratoacanthoma. The lower lid was most commonly involved in cases of keratoacanthoma (50.0%). Six
patients (60.0%) underwent Mohs surgery, and four (40.0%) were treated with excision under frozen
section control. There were no cases of recurrence during a mean follow up period of 21 (SD 13) months.
Conclusion: Although the clinical presentation of periocular keratoacanthoma is usually characteristic, a
significant percentage of patients will prove to have invasive SCC. Complete excision with margin control
offers a definitive diagnosis, as well as tissue conservation and a low recurrence rate.
K
eratoacanthoma is a unique entity in skin cancer,
characterised by a very rapid growth phase, followed
by gradual involution.1–5 Some authors see it as a
distinctive tumour,1–3 whereas others define it as a subtype of
squamous cell carcinoma (SCC), and treat it accordingly.4 5
The tumour is most commonly seen on sun exposed and
hair bearing areas of elderly patients, mainly on the face,
forearms, and hands.3 4 Periocular involvement is not
common, and there are only a few series on the clinical
presentation and treatment of keratoacanthoma in this
area.6–10
Although the morphological features of keratoacanthoma
are quite distinctive, a definite distinction from invasive SCC
can only be made histologically. In this retrospective series
we review all cases of periocular tumours diagnosed as
keratoacanthoma based on the clinical presentation and
discuss the cases eventually diagnosed with invasive SCC.
METHODS
This is a retrospective, non-comparative, interventional case
series of all patients with periocular tumours which were
diagnosed as keratoacanthoma based on the clinical and
morphological features and a preoperative biopsy. All
patients were seen at the Oculoplastic Unit at the Royal
Adelaide Hospital between 1998 and 2004. The patient
database was reviewed and all patients who had a
preoperative diagnosis of keratoacanthoma were selected.
The main data recorded were patients’ demographics,
duration of tumour, tumour site, preoperative tumour size,
histological diagnosis and evidence of perineural invasion,
number of excision levels, postoperative defect size, recur-
rence post-treatment, and postoperative complications.
The final diagnosis in all patients was based on the
histological analysis of the resected tumours by an experi-
enced dermatopathologist.
RESULTS
There were 12 patients (eight males, four females) who were
diagnosed with keratoacanthoma based on the clinical
tumour characteristics. An initial incisional biopsy in all
cases showed a squamo-proliferative process, but after
complete tumour removal, the final histological diagnosis of
keratoacanthoma was confirmed in 10 patients (83.3%)
(table 1). The other two patients (16.7%) were diagnosed
with an invasive (moderate to well differentiated) SCC
(table 2).
The 10 patients with a confirmed diagnosis of kerato-
acanthoma included six males and four females with a mean
(standard deviation) age of 67 (SD 12) years (median 70;
range 41–81) (table 1). The mean duration from tumour
appearance to clinical diagnosis was 10 (SD 5) weeks
(median 8; range 4–20 weeks). The tumour was located in
the lower lid in five cases (50%), upper lid in two cases (20%),
medial canthus in two cases (20%), and lateral canthus in
one case (10%). There was an equal distribution between
the right and left sides (50%). Mean tumour size was 12
(SD 6) mm (median 10.5; range 5–20 mm).
Six patients (60%) underwent Mohs surgery, and four
(40%) were treated with excision under frozen section
control. No cases of perineural or vascular invasion were
noted on final histology. The various reconstruction methods
used are presented in table 1. There were no cases of
complications or recurrence during a mean follow up of 21
(SD 13) months (median 18; range 6–43 months).
DISCUSSION
Keratoacanthoma was first described by Hutchinson,11 more
than 115 years ago, as a ‘‘crateriform ulcer of the face’’, and
since then it continues to be a source of debate as to the exact
pathogenesis and preferred management.1–5
The predilection of keratoacanthoma for sun exposed areas
suggests ultraviolet (UV) radiation is an important aetiolo-
gical factor. Other possible factors in the pathogenesis
include immunosuppression, exposure to chemical agents,
human papilloma virus infection, chronically injured skin
(ulcers, burns, sinus tracts, vaccination scars, and chronic
skin diseases), and genetic aberrations.3–5
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The annual incidence of cutaneous keratoacanthoma varies
according to geographical location. It was estimated to be 104
cases per 100 000 in Hawaii,12 and as high as 150 cases per
100 000 in the northern areas of Australia.13 It commonly
affects patients in their fifth to seventh decades, and in most
series appears to be much more common in males.1 3–5 In our
series there was a slight male predominance (55.6%), and the
mean age (67 (SD 13) years) was similar to other reports on
cutaneous keratoacanthoma. The exact reason for the male
predominance in these series is not clear.
Although there is an obvious predilection of the tumour for
the face,1 3 periocular involvement is uncommon and has
been reported in only a small number of series in the
ophthalmic literature. In one of the earliest series, Baer and
Kopf reviewed 592 cases of keratoacanthoma, and found that
more than 70% of tumours were located on the face, and 33
cases were periocular (5.6%).14 Boniuk and Zimmerman
reported a large series of 44 patients with periocular
keratoacanthoma; 58% were located on the lower lid, 35%
on the upper lid, and 7% on the medial or lateral canthi.6 In a
recent report, Donaldson et al reported another 10 patients
with periocular keratoacanthoma; 50% of the lesions were
located on the lower lid, 20% on the upper lid, 20% on the
medial canthus, and 10% on the lateral canthus.10 Similar
distribution was found in our series. This distribution
correlates with the degree of sun exposure, and is also found
in other UV induced periocular tumours, such as basal cell
carcinoma and squamous cell carcinoma.
Solitary keratoacanthomas are characterised by three
clinical stages: (1) a proliferative/growth phase which lasts
2–10 weeks, (2) a stationary period of similar duration, and
(3) resolution/involution phase of up to one year duration.3
There are also several variants of keratoacanthoma which are
of clinical importance: the giant keratoacanthoma (exceeding
3 cm in diameter), keratoacanthoma centrifugum margin-
atum (characterised by progressive peripheral growth and
ventral healing), subungal keratoacanthoma (painful
destructive keratoacanthoma of the nail), mucosal kerato-
acanthoma (affecting mucous membranes), and multiple
keratoacanthomas (usually associated with the Ferguson
Smith type, the Grzybowski type, Muire-Torre syndrome, and
xeroderma pigmentosum).1 3 5 During the proliferative phase,
a firm hemispheric papule grows rapidly. The border of the
papule is skin coloured or slightly erythematous, and fine
telangiectatic vessels may be evident.4 When it reaches its
mature form, it is bud shaped or dome shaped, with a central,
umbilicated, keratinous core. All our patients presented with
this characteristic tumour morphology (fig 1A and 1B) and
a history of a rapidly growing lesion (mean duration
from tumour appearance to clinical diagnosis was 10
(SD 5) weeks; range 4–20 weeks), and this was the basis
for the initial clinical diagnosis of keratoacanthoma. The
mean tumour size in our series was 12 (SD 6) mm (range
5–20 mm). Boniuk and Zimmerman reported that 82% of the
tumours were present for less than two months, and most
lesions were smaller than 8 mm.6 Donaldson et al found a
slightly longer duration of symptoms before diagnosis (mean
5.4 months; median 3 months), but a similar tumour size
(mean 7.2 mm; range 2–25 mm).10 Interestingly, while
reviewing the literature, we found no cases of giant
periocular keratoacanthomas (measuring more 30 mm),
and the majority of reported tumours were smaller than
10 mm.
Shave or incisional punch biopsies are usually inadequate
to diagnose keratoacanthoma, and the definite diagnosis can
only be established after tumour excision, based on the
cytological and architectural findings.4 Histologically, mature
lesions demonstrate a central keratin-filled crater with a
surrounding buttress of epidermis (fig 2A). They are
composed of tumour islands made of enlarged keratinocytes
with a pale cytoplasm, arranged in concentric layers with
increasing keratinisation centrally (fig 2B). These cell nests
extend to the dermis, to the level of the sweat glands. The
large cells with pink cytoplasm towards the centre of the
tumour cell nests are generally more characteristic of
keratoacanthoma.1 3 Inflammatory cells are usually found in
the stroma, at the base of the lesion. The distinction between
keratoacanthoma and SCC is not always simple. Various
markers such as involucrin and lectins were not specific
enough, and could not be used in clinical practice.3 5 In a















1 41/M LL 6 5 MMS 768 1 Primary closure 12 No
2 76/F LL 8 8 F/S 11610 1 Tenzel flap 29 No
3 57/M LL 20 20 F/S 24622 1 Hughes flap 43 No
4 81/M LC 7 16 F/S 1068 1 FTSG 14 No
5 74/F UL 12 9 MMS 15616 2 Reverse Tenzel 21 No
6 68/M LL 8 8 F/S 10611 1 Tenzel flap 12 No
7 58/F UL 16 19 MMS 18619 2 Tarsoconjunctival
transposition
35 No
8 77/M MC 10 12 MMS 12612 1 FTSG 30 No
9 72/F MC 4 5 MMS 667 1 Bilobed flap 8 No
10 64/M LL 5 17 MMS 25620 3 Hughes flap 6 No
UL, upper lid; MC, medical canthus; LL, lower lid; MMS, Mohs micrographic surgery; F/S, frozen section control; FTSG, full thickness skin graft.




















1 60/M LL 8 6 MMS 14616 3 Well diff SCC, + PNI Hughes flap 17 No
2 70/M LL 8 10 F/S 17612 1 Mod/ well diff SCC,
no PNI
Tenzel flap 5 No
LL, lower lid; MMS, Mohs micrographic surgery; SCC, squamous cell carcinoma; PNI, perineural invasion; F/S, frozen section control.
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recent report by Cribier et al the authors studied 296 fully
excised tumours, previously classified as keratoacanthoma or
SCC, and analysed the histopathological criteria differentiat-
ing the two tumours.15 They concluded that the most
important criteria were an epithelial lip and a sharp outline
demarcation between the tumour and the stroma (favouring
keratoacanthoma), and ulceration, pleomorphism/anaplasia,
and numerous mitoses (favouring SCC). Perineural invasion
(PNI) is an uncommon finding in keratoacanthoma, and
when present, it does not affect prognosis or the risk of
metastatic disease.2 16 No cases of PNI were recorded in any of
our keratoacanthoma patients. One of our other two patients,
with a final diagnosis of SCC, was also diagnosed with
intratumoural PNI.
It is well recognised that keratoacanthomas can regress
spontaneously, without any treatment.17 During the involu-
tional phase the lesion becomes flattened and less crateri-
form, and granulation tissue appears at the base, resulting in
a scar at the area of the tumour. Most authors advocate
complete excision of the tumour as opposed to conservative
management. Tumour excision provides tissue for accurate
histological diagnosis, hastens cure, prevents rapid growth,
and maintains normal function of involved organs. Another
factor which favours complete removal of keratoacanthomas
is the significant overlap in the clinical and histological
appearance of keratoacanthoma and invasive SCC, which
may possibly lead to misdiagnosis of SCC as kerato-
acanthoma. In addition, the initial lesion may be a combined
keratoacanthoma and SCC, or there could have been a
transformation to SCC at some point in the evolution.2
Early excision of periocular keratoacanthoma is essential,
not only to maintain normal eyelid function, but also to
prevent further tissue destruction and invasion into deeper
tissues. This is supported by Grossniklaus et al who presented
three cases of invasive keratoacanthoma; one involved
skeletal muscle and two had PNI (one of them extending
into the cavernous sinus).9 The importance of complete
excision of keratoacanthoma is further emphasised by our
findings that 16.7% of the lesions in our study, initially
diagnosed as keratoacanthoma based on the clinical pre-
sentation (fig 3A) and initial biopsy, eventually proved to be
invasive SCC (fig 3B and 3C). When left untreated, these
aggressive tumours can be locally destructive, invade the
orbit,18 metastasise,19 and even result in death.20 Therefore,
the role of alternate treatments such as curettage and
electrodissection, cryotherapy, radiotherapy, or intralesional
chemotherapy, is probably limited to patients unable to
tolerate surgery. Hence, it is generally accepted that surgical
excision with margin control is the most appropriate method
for solitary tumours, with recurrence rates of 4–8% for
cutaneous keratoacanthomas.4 5 Boniuk and Zimmerman
treated most of their 44 periocular keratoacanthomas with
surgical excision (margin control was not specified), and had
no cases of recurrence during a follow up period ranging from
8 months to 11 years.6 Donaldson et al treated all their
patients with surgical excision (five of them were margin
controlled with frozen section), and on pathological exam-
ination, all lesions were shown to be completely excised, with
clear margins.10 They noted no cases of recurrence during a
mean follow up period of 34.5 months. Six patients (60%)
in our series underwent Mohs surgery, and four (40%)
underwent tumour excision with frozen section control.
There were no cases of recurrence during a mean follow up of
Figure 1 The mature phase of a left lower lid keratoacanthoma.
(A) A large central keratinous core. (B) A narrow central core.
Figure 2 Keratoacanthoma. (A) A central keratin-filled crater with a
surrounding buttress of epidermis (haematoxylin and eosin620
magnifications). (B) Islands of enlarged keratinocytes with a pale
cytoplasm, arranged in concentric layers with increasing keratinisation
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21 months (range 8–40 months). There are only a few
studies on the role of Mohs surgery in the treatment of
keratoacanthoma, and none of these studies referred
specifically to periocular tumours. Mohs treated 115 patients
with keratoacanthoma, and recorded no cases of recurrence.
Larson reported 43 patients with keratoacanthomas treated
with Mohs surgery, most of them were located on the face.
The recurrence rate in his series was 2.4%.22
In conclusion, periocular keratoacanthoma is a rare
tumour that can be locally destructive and invasive.
Although the clinical and morphological presentation is
characteristic in most cases, it cannot always be differen-
tiated from invasive SCC, and a definite diagnosis requires
complete tumour excision. Our series suggests that a
significant proportion of tumours that clinically are thought
to be keratoacanthoma will prove to be invasive SCC. Hence,
we believe there is no role for observation, curettage, or
alternate destructive treatment modalities in the majority of
patients. Surgical excision with margin control using frozen
sections or Mohs surgery should be considered for lesions in
the periocular area as it offers definitive diagnosis, tissue
conservation, and a low recurrence rate.
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Figure 3 (A) Right lower lid rapidly growing crater shaped tumour
diagnosed clinically as keratoacanthoma. (B) Nests of squamous
epithelial cells arising from the epidermis and extend into the dermis,
consistent with an invasive SCC (haematoxylin and eosin620
magnifications). (C) Cells show abundant eosinophilic cytoplasm and
large vesicular nuclei (haematoxylin and eosin6200 magnifications).
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